Replies to post #221624 on Biotech Values

[DewDiligence]

What % of GILD’s $98M QoQ decline in 3Q18 HCV sales was due to each of the following: a) Fewer HCV patients treated; b) Lower ASP; c) Loss of market share to Mavyret?

[DewDiligence]

GILD 4Q18 HCV sales=$738M, -18% QoQ:

https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-sciences-announces-fourth-quarter-and-full-year-2018-financial-results

4Q18 US HCV sales were $420M, -14% QoQ; 4Q18 ex-US HCV sales were $318M, -23% QoQ